Spare a thought for your Scandinavian colleagues who are running CROs
Spare a thought for your Scandinavian colleagues who are running CROs: staff turnover among companies in Norway was 47% in 2015, and the comparable figure for Denmark was 43%, according to the 18th annual CRO Industry Global Compensation and Turnover Survey conducted by HR+Survey Solutions, LLC.
More than half of the countries surveyed (24 of the 45) had average turnover of 20% or more. Others with high turnover rates were India (36%), New Zealand (33%), and Switzerland (30%), Taiwan (29%), Finland (28%), and China (28%).
In the U.S., overall staff turnover increased slightly to 20.1% in 2015 from 19.5% in 2014 for all positions in CROs. Turnover in the U.S. for clinical monitoring jobs at CROs remained high at 25.1% in 2015, compared with 25.4% in 2014, 16.4% in 2013, 24.4% in 2012, and 29.4% in 2011.
U.S. unemployment has continued to decline since it peaked in 2009, and currently is well below 5%. This means that CROs have an uphill battle identifying new talent sources.
“Turnover is a significant business issue; high turnover can undermine the relationship with a sponsor,” noted Judy Canavan, managing partner of HR+Survey Solutions and the author of the study. “Employees have figured out that changing jobs is the key to maximizing their compensation and rounding out their CV, companies need to create internal career opportunities.”
According to Canavan, the number of registered clinical trials has risen sharply from 24,921 in 2005 to 231,508 as of December 4, 2016 (source: http://clinicaltrials.gov/ct2/resources/trends).
Other findings of the survey were:
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.